These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17992397)

  • 1. Does the use of paclitaxel or rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent?
    Lemos HP; Atallah AN
    Sao Paulo Med J; 2007 Jul; 125(4):242-5. PubMed ID: 17992397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sirolimus-eluting stents with paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter Southern California Registry).
    Lee MS; Hu PP; Aragon J; Shah AP; Oyama J; Dhoot J; Iqbal Z; Jones N; Penny W; Tobis J; Mahmud E; French W
    Am J Cardiol; 2010 Aug; 106(3):337-41. PubMed ID: 20643242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
    Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
    JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis.
    Doggrell SA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2209-20. PubMed ID: 15500367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
    Stone GW; Ellis SG; Cannon L; Mann JT; Greenberg JD; Spriggs D; O'Shaughnessy CD; DeMaio S; Hall P; Popma JJ; Koglin J; Russell ME;
    JAMA; 2005 Sep; 294(10):1215-23. PubMed ID: 16160130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
    Windecker S; Remondino A; Eberli FR; Jüni P; Räber L; Wenaweser P; Togni M; Billinger M; Tüller D; Seiler C; Roffi M; Corti R; Sütsch G; Maier W; Lüscher T; Hess OM; Egger M; Meier B
    N Engl J Med; 2005 Aug; 353(7):653-62. PubMed ID: 16105989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes with coronary artery bypass graft surgery versus percutaneous coronary intervention for patients with diabetes mellitus: can newer generation drug-eluting stents bridge the gap?
    Bangalore S; Toklu B; Feit F
    Circ Cardiovasc Interv; 2014 Aug; 7(4):518-25. PubMed ID: 24939927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
    Sethi A; Bahekar A; Bhuriya R; Bajaj A; Singh PP; Arora R; Khosla S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):544-56. PubMed ID: 23177483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis).
    Indolfi C; Pavia M; Angelillo IF
    Am J Cardiol; 2005 May; 95(10):1146-52. PubMed ID: 15877984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and economic analysis of drug-eluting coronary stents available in Australia.
    Lord SJ; Howard K; Allen F; Marinovich L; Burgess DC; King R; Atherton JJ
    Med J Aust; 2005 Nov; 183(9):464-71. PubMed ID: 16274347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents.
    Malenka DJ; Kaplan AV; Lucas FL; Sharp SM; Skinner JS
    JAMA; 2008 Jun; 299(24):2868-76. PubMed ID: 18577731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.
    Barlis P; Kaplan S; Dimopoulos K; Ferrante G; Di Mario C
    Cardiology; 2008; 111(4):270-6. PubMed ID: 18451644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.